228 related articles for article (PubMed ID: 19351859)
1. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1.
Wang MY; Chen PS; Prakash E; Hsu HC; Huang HY; Lin MT; Chang KJ; Kuo ML
Cancer Res; 2009 Apr; 69(8):3482-91. PubMed ID: 19351859
[TBL] [Abstract][Full Text] [Related]
2. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway.
Chen PS; Wang MY; Wu SN; Su JL; Hong CC; Chuang SE; Chen MW; Hua KT; Wu YL; Cha ST; Babu MS; Chen CN; Lee PH; Chang KJ; Kuo ML
J Cell Sci; 2007 Jun; 120(Pt 12):2053-65. PubMed ID: 17550972
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
5. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.
Vellon L; Menendez JA; Lupu R
Mol Carcinog; 2006 Oct; 45(10):795-804. PubMed ID: 16705745
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner.
Vellon L; Menendez JA; Liu H; Lupu R
Differentiation; 2007 Nov; 75(9):819-30. PubMed ID: 17999741
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
10. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
Ren Y; Chen Z; Chen L; Woods NT; Reuther GW; Cheng JQ; Wang HG; Wu J
J Biol Chem; 2007 Dec; 282(50):36463-73. PubMed ID: 17942397
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.
Flores ML; Castilla C; Ávila R; Ruiz-Borrego M; Sáez C; Japón MA
Breast Cancer Res Treat; 2012 Jun; 133(3):917-28. PubMed ID: 22076480
[TBL] [Abstract][Full Text] [Related]
12. CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.
Tsai HC; Huang CY; Su HL; Tang CH
Biochim Biophys Acta; 2014 May; 1843(5):846-54. PubMed ID: 24462773
[TBL] [Abstract][Full Text] [Related]
13. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
14. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Menendez JA; Vellon L; Mehmi I; Teng PK; Griggs DW; Lupu R
Oncogene; 2005 Jan; 24(5):761-79. PubMed ID: 15592521
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
Huo X; Zhang Q; Liu AM; Tang C; Gong Y; Bian J; Luk JM; Xu Z; Chen J
Oncol Rep; 2013 Feb; 29(2):840-6. PubMed ID: 23232767
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance.
Fernández Y; España L; Mañas S; Fabra A; Sierra A
Cell Death Differ; 2000 Apr; 7(4):350-9. PubMed ID: 10773819
[TBL] [Abstract][Full Text] [Related]
18. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line.
Fiebig AA; Zhu W; Hollerbach C; Leber B; Andrews DW
BMC Cancer; 2006 Aug; 6():213. PubMed ID: 16928273
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy against Bcl-2-related proteins in breast cancer cells.
Emi M; Kim R; Tanabe K; Uchida Y; Toge T
Breast Cancer Res; 2005; 7(6):R940-52. PubMed ID: 16280040
[TBL] [Abstract][Full Text] [Related]
20. CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells.
Tan TW; Lai CH; Huang CY; Yang WH; Chen HT; Hsu HC; Fong YC; Tang CH
J Cell Biochem; 2009 May; 107(2):345-56. PubMed ID: 19301259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
